Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Colorectal cancer (CRC) is a significant global health concern, originating from precancerous polyps in the colon or rectum and progressing through ...

Technology company Tempus AI has announced the acquisition of Paige, a company focused on digital pathology and AI, for a ...

The Methodist Church, Ghana, has commemorated its 190th anniversary celebration of its existence in Ghana with a grand durbar ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a recent update, Eli Lilly and Company announced the ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a significant advancement for cancer ...

© 2001-2025 Plasteurope.com | Imprint | Privacy | Cookie settings ...